Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:00858'
s EV-to-FCF Range Over the Past 10 Years
Min: -258.83 Med: -22.02 Max: 683.65
Current: 71.54
During the past 13 years, the highest EV-to-FCF of Extrawell Pharmaceutical Holdings was 683.65. The lowest was -258.83. And the median was -22.02.
HKSE:00858's EV-to-FCF is ranked worse than 83.07% of 573
companies
in the Drug Manufacturers industry
Industry Median: 19.09
vs HKSE:00858: 71.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Extrawell Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:
Extrawell Pharmaceutical Holdings's share price for today is HK$0.083.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Extrawell Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$-0.395.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Extrawell Pharmaceutical Holdings EV-to-FCF Related Terms
Extrawell Pharmaceutical Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extrawell Pharmaceutical Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Extrawell Pharmaceutical Holdings's EV-to-FCF falls into.
Extrawell Pharmaceutical Holdings's current Enterprise Value is HK$217.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Extrawell Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was HK$3.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extrawell Pharmaceutical Holdings (HKSE:00858) has a EV-to-FCF of 71.54 as of Sep. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Extrawell Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Extrawell Pharmaceutical Holdings ranks #476 out of 573 companies in the Drug Manufacturers industry, placing it in the top 83.1%.
Is Extrawell Pharmaceutical Holdings' EV-to-FCF too high?
Extrawell Pharmaceutical Holdings' current EV-to-FCF is 71.54. The Drug Manufacturers industry median EV-to-FCF is 19.09. Extrawell Pharmaceutical Holdings' value of 71.54 is 274.8% above this industry median. Based on the distribution chart, Extrawell Pharmaceutical Holdings ranks #476 out of 573 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Extrawell Pharmaceutical Holdings' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Extrawell Pharmaceutical Holdings ranks #476 out of 573 companies for EV-to-FCF. This places Extrawell Pharmaceutical Holdings in the lower half of its industry. The industry median EV-to-FCF is 19.09. Extrawell Pharmaceutical Holdings' value of 71.54 is 274.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.09, based on 573 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extrawell Pharmaceutical Holdings's current EV-to-FCF of 71.54 is 274.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Extrawell Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current EV-to-FCF is 71.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 66% above its estimated fair value. The current EV-to-FCF is 71.54 and 274.8% above the Drug Manufacturers industry median of 19.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current EV-to-FCF is 71.54 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00858 has been successfully added to your 
